←Back to Expert Scholars
Translational Medicine / 转化医学NICHE-2 Neoadjuvant IO
Myriam Chalabi
MD, PhD
🏢Netherlands Cancer Institute🌐Netherlands
Medical Oncologist
50
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Myriam Chalabi led the NICHE-2 trial demonstrating that neoadjuvant nivolumab plus ipilimumab produces major pathologic responses in nearly all dMMR colon cancers. Her work established neoadjuvant IO as a paradigm-shifting approach for localized MSI-H disease.
Share:
🧪Research Fields 研究领域
NICHE-2 trial
neoadjuvant nivolumab ipilimumab
dMMR colon cancer
pathologic complete response
perioperative IO
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Myriam Chalabi 的研究动态
Follow Myriam Chalabi's research updates
留下邮箱，当我们发布与 Myriam Chalabi（Netherlands Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment